YANTAI, China I August 18, 2025 I RemeGen Co., Ltd. (Stock Code: 688331.SH/09995.HK, "RemeGen"), a leading Chinese biopharmaceutical company, announced today ...

STUTTGART, Germany I August 19, 2025 I La Merie Publishing announced the release of the free report Pipeline of 5T4-Targeted Immunotherapies to showcase its newest service of pipeline reviews. The ...

The initiative aims to identify and support new ideas for innovative oral formulations for peptide drugs such as GLP-1 receptor agonists via BioMed X’s global ...

NEEDHAM, MA, USA I August 18, 2025 I Stealth BioTherapeutics, a clinical-stage biotechnology company focused on the discovery, development and ...

SAN DIEGO, CA, USA I August 18, 2025 I Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based ...

Filings both for the obicetrapib monotherapy and obicetrapib plus ezetimibe fixed-dose combination submitted to EMA by our partner, Menarini, for treatment ...

OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumors ...

NEWPORT BEACH, CA, USA I August 18, 2025 I jCyte, Inc. is pleased to announce the first patients have been enrolled and treated in the JC02-88 study ...

HANGZHOU, China I August 18, 2025 I Hangzhou Qihan Biotech Co., Ltd. ("Qihan" or "Qihan Biotech" or "the Company"), an industry leader in applying ...

RESEARCH TRIANGLE PARK, NC, USA I August 18, 2025 I Opus Genetics (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases ...

NEW YORK, NY, USA I August 15, 2025 I Pfizer Inc. (NYSE: PFE) today announced results from the Phase 3 THRIVE-131 study evaluating inclacumab, an ...

SÖDERTÄLJE, Sweden I August 18, 2025 I Anocca AB (‘Anocca’ or the ‘Company’), a leading clinical-stage T-cell immunotherapy company, has successfully raised ...